- Home
- OGEN vs CVKD Comparison
OGEN vs CVKD Comparison
Compare OGEN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- CVKD
- Stock Information
- Founded
- OGEN 1996
- CVKD 2022
- Country
- OGEN United States
- CVKD United States
- Employees
- OGEN N/A
- CVKD N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- OGEN Health Care
- CVKD Health Care
- Exchange
- OGEN Nasdaq
- CVKD Nasdaq
- Market Cap
- OGEN 4.5M
- CVKD 17.1M
- IPO Year
- OGEN N/A
- CVKD 2023
- Fundamental
- Price
- OGEN $0.34
- CVKD $14.45
- Analyst Decision
- OGEN
- CVKD Strong Buy
- Analyst Count
- OGEN 0
- CVKD 2
- Target Price
- OGEN N/A
- CVKD $52.50
- AVG Volume (30 Days)
- OGEN 389.1K
- CVKD 59.6K
- Earning Date
- OGEN 11-07-2024
- CVKD 11-08-2024
- Dividend Yield
- OGEN N/A
- CVKD N/A
- EPS Growth
- OGEN N/A
- CVKD N/A
- EPS
- OGEN N/A
- CVKD N/A
- Revenue
- OGEN $7,466.00
- CVKD N/A
- Revenue This Year
- OGEN N/A
- CVKD N/A
- Revenue Next Year
- OGEN N/A
- CVKD N/A
- P/E Ratio
- OGEN N/A
- CVKD N/A
- Revenue Growth
- OGEN N/A
- CVKD N/A
- 52 Week Low
- OGEN $0.29
- CVKD $5.40
- 52 Week High
- OGEN $7.74
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- OGEN 37.15
- CVKD 56.80
- Support Level
- OGEN $0.29
- CVKD $11.19
- Resistance Level
- OGEN $0.45
- CVKD $17.95
- Average True Range (ATR)
- OGEN 0.04
- CVKD 1.37
- MACD
- OGEN 0.02
- CVKD 0.10
- Stochastic Oscillator
- OGEN 28.88
- CVKD 49.64
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.